Latest research on Herceptin

A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*

Latest findings

Herceptin has shown clinical efficacy in ErbB2-overexpressing breast cancer patients, and is now being used for the treatment of advanced breast cancer [26]. [source, 2000]
First, the discovery that human epidermal growth factor receptor-2 (HER-2) was amplified and overexpressed in 20-30% of primary breast cancers and can induce mammary carcinomas in transgenic mice led to its subsequent use as a predictive marker of chemotherapeutic selection, and as a target for an effective antibody-based therapy (Herceptin ®; Genentech Inc, San Francisco, California, USA). [source, 2000]
Herceptin is the first of a new generation of non-cytotoxic, non-hormonal compounds showing considerable promise in the management of metastatic breast cancer. [source, 2000]
Two pivotal trials were initiated, with one investigating the use of Herceptin in patients failing one or two prior chemotherapy regimens for metastatic breast cancer. [source, 2000]
In the other pivotal trial, patients were randomized to chemotherapy alone or with Herceptin as first-line therapy for metastatic breast cancer. [source, 2000]
Women who had not received prior anthracycline therapy were randomized to anthracycline ± Herceptin, while patients with prior adjuvant anthracycline were randomized to paclitaxel ± Herceptin. [source, 2000]
Herceptin plus chemotherapy was superior to chemotherapy alone in all parameters of effectiveness, including a 5-month survival advantage at two years of follow-up. [source, 2000]
Antibodies directed against the HER2/neu protein have attracted a lot of attention recently because of the availability of the monoclonal antibody Herceptin for treatment of breast cancer [14]. [source, 1999]
Interestingly, the Herceptin Adjuvant (HERA) trial demonstrated that two years of trastuzumab therapy did not provide a greater survival advantage than one year [12]. [source]
Molecular therapies that target HER2 include the monoclonal anti-HER2 antibody trastuzumab (Herceptin) and pertuzumab (Perjeta) (Genentech, South San Francisco, CA), and TYROSINE kinase inhibitors, such as lapatinib (Tykerb) (GlaxoSmithKline, Middlesex, UK) [42]. [source]